

Revised: September 2009 (8th version)

Standard Commodity Classification No. of Japan
871339

- Antidinic -

## Travelmin<sup>®</sup> Combination Tablet

Storage
TRAVELMIN should be stored at room temperature.
Expiration date
TRAVELMIN should be used before the expiration date indicated on the package.

Approval No.	22100AMX01360000
Date of listing in the NHI reimbursement price	Sep 2009
Date of initial marketing in Japan	May 1952
Date of latest reevaluation	Sep 1984

### CONTRAINDICATIONS (TRAVELMIN is contraindicated in the following patients.)

1. Patients with glaucoma  
[TRAVELMIN may increase intraocular pressure due to its anticholinergic action.]
2. Patients with obstructive diseases of the lower urinary tract such as a prostatic hypertrophy  
[TRAVELMIN may cause dysuria, urinary retention or other symptoms due to its anticholinergic action.]




### DESCRIPTION

#### 1. Composition

Each white tablet contains 40 mg of diphenhydramine salicylate and 26 mg of diprophylline.

It also contains acetylglycerin fatty acid ester, carmellose calcium, light anhydrous silicic acid, microcrystalline cellulose, hydrogenated oil, saccharin sodium hydrate, potassium bitartrate, calcium stearate, talc, corn starch, lactose hydrate, povidone, macrogol 6000, D-mannitol, dibasic calcium phosphate hydrate and flavor.

#### 2. Product description

Brand name	Dosage form and identification code	Appearance			Description
		Face	Reverse	Lateral	
TRAVELMIN Combination Tablet	Tablets				White Dry-coated tablets
	EISAI EISAI	Diameter (mm) 10.6	Weight (mg) 400	Thickness (mm) 3.5	

### INDICATIONS

Nausea, vomiting and vertigo resulting from the following diseases or conditions.

Motion sickness

Ménière's syndrome

### DOSAGE AND ADMINISTRATION

The usual adult dose for oral use is one tablet each time.

If necessary, take three to four times daily.

The dose may be adjusted depending on the patient's age and symptoms.

### PRECAUTIONS

#### 1. Careful Administration (TRAVELMIN should be administered with care in the following patients.)

- (1) Patients with epilepsy  
[Seizures may be caused by central nervous system (CNS) stimulation.]
- (2) Patients with hyperthyroidism  
[Hypermetabolism accompanying hyperthyroidism and the action of catecholamines may be potentiated.]
- (3) Patients with acute nephritis  
[TRAVELMIN may increase kidney load.]

#### 2. Important Precautions

Since TRAVELMIN may induce drowsiness, patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.

#### 3. Drug Interactions

**Precautions for coadministration (TRAVELMIN should be administered with care when coadministered with the following drugs.)**

Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
Central nervous system suppressants Barbituric acid derivatives Phenothiazine derivatives Alcohol	Since TRAVELMIN contains diphenhydramine salicylate, they may mutually potentiate each other's action. Care should be exercised in coadministration such as reducing the dosage of the drugs.	The central nervous system suppressing actions are additively potentiated.
Monoamine oxidase inhibitor (MAO-I)		MAO-I interferes with the antidotal mechanism of TRAVELMIN, prolonging and potentiating its action.
Other xanthine derivatives Theophylline Aminophylline hydrate Choline theophylline Caffeine hydrate, etc. CNS stimulants Ephedrine hydrochloride Ephedra herb, etc.	Diprophylline, an ingredient of TRAVELMIN, may cause excessive CNS stimulation. Caution should be exercised with respect to adverse reactions. In the event of abnormal findings, appropriate measures, such as discontinuation of the medication or reduction in dosage, should be taken.	When concomitantly administered with these drugs, CNS stimulation may be potentiated.

#### 4. Adverse Reactions

Adverse reactions were reported in 39 of 448 patients (8.71 %). (At the end of the reevaluation period)

	5% > ≥0.1%	Incidence unknown
Hypersensitivity <sup>(note)</sup>		Rash
Cardiovascular	Palpitations	
Psychoneurologic	Sleepiness, malaise, dull headache and vertigo	Headache and nervousness
Gastrointestinal	Thirst	Nausea/vomiting and diarrhea

Note) In the event of such symptoms, TRAVELMIN should be discontinued.

#### 5. Use in the Elderly

Dosage adjustment or other appropriate measures considered when prescribing this drug to elderly patients, because these patients may be more sensitive than younger patients to the effect of this drug.

#### 6. Use during Pregnancy, Delivery or Lactation

(1) The use of this drug in pregnant women or in women who may possibly pregnant is not recommended.

[The safety of TRAVELMIN in pregnant women has not been established.]

(2) It is advisable to avoid using this drug in lactating mothers. If the use of this drug judged to be essential, breast feeding must be discontinued during treatment.

[Animal studies (in rats) have shown that diphenhydramine is secreted in breast milk.]

#### 7. Precautions concerning Use

Oral administration

Patients should be instructed not to chew the tablets, because this will produce a bitter taste in the mouth and numbness of the tongue may occur.

#### CLINICAL STUDIES

The results of clinical trials in Japan involving a total of 448 patients are summarized below.

##### 1. For motion sickness

The efficacy rate was 91.55% (336/367 patients) for motion sickness such as seasickness and car sickness.

##### 2. For Ménière's syndrome

The efficacy rate was 86.89% (53/61 patients) for symptoms of vertigo in Ménière's syndrome, peripheral vertigo disease, etc.

#### PHARMACOLOGY

##### 1. Sedation of labyrinthine reflex

TRAVELMIN showed marked sedation of the labyrinthine reflex when given to healthy human volunteers whose labyrinths had been stimulated experimentally, and rabbits with experimentally created labyrinthine disequilibrium. TRAVELMIN was also effective for otogenic vertigo (acute ictal vertigo).<sup>1)</sup>

##### 2. Suppression of vomiting center excitation

In an experiment on dogs, diphenhydramine was observed to suppress excitation of the vomiting center which causes nausea and vomiting.<sup>2)</sup>

#### PHYSICOCHEMISTRY

##### 1. Nonproprietary name: Diphenhydramine Salicylate


**Chemical name:** 2-benzhydroxy-*N,N*-dimethylethylamine salicylate

**Molecular formula:** C<sub>17</sub>H<sub>21</sub>NO · C<sub>7</sub>H<sub>6</sub>O<sub>3</sub>

**Molecular weight:** 393.48

**Structural formula:**

Diphenhydramine Salicylate



##### Description:

Diphenhydramine salicylate occurs as white crystals or a crystalline powder. It is odorless and has no taste at first, but later a slightly bitter taste and numbness of the tongue develops. It is freely soluble in methanol, in acetic acid (100) and in acetone, soluble in ethanol (95) and slightly soluble in water. It is affected by light gradually. Melting point : 107-109°C


##### 2. Nonproprietary name: Diprophylline

**Chemical name:** 7-(2, 3-dihydroxypropyl) theophylline (Another name: Dyphylline)

**Molecular formula:** C<sub>10</sub>H<sub>14</sub>N<sub>4</sub>O<sub>4</sub>

**Molecular weight:** 254.25

**Structural formula:**



##### Description:

Diprophylline occurs as a white powder or granules. It is odorless and has a bitter taste. It is freely soluble in water, slightly soluble in ethanol (95) and practically insoluble in diethyl ether.

**Melting point:** 160-164°C

#### PACKAGING

**TRAVELMIN Combination Tablet:**

Boxes of 120 in heat sealed packages

#### REFERENCES

- 1) Watanabe I. et al.: Otolaryngology. Head Neck Surg. **25**, 1, 1953.
- 2) HISAMOTO K.: Okayama Igakkai Zasshi, **65**, 145, 1953.

**REQUEST FOR LITERATURE SHOULD BE MADE TO:**

Safety Management Department

Fax: 03-3811-2710

Eisai Co., Ltd.

**REQUEST FOR DRUG INFORMATION SHOULD BE  
MADE TO:**

Customer Information Service

Free Dial: 0120-419-497

Eisai Co., Ltd.

**Manufactured and marketed by:**

Sannova Co., Ltd.

3038-2, Serada-cho, Ota-shi, Gunma, 370-0426

**Marketed by:**

Eisai Co., Ltd.

6-10, Koishikawa 4-chome, Bunkyo-ku, Tokyo, 112-8088